SALT
LAKE CITY, Oct. 21, 2024 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that Co-Diagnostics will be hosting a booth at
Africa Health/Medlab Africa in Cape Town,
South Africa on October 22-24,
2024.
The conference website describes it as the largest gathering of
healthcare companies, technology, products and services in the
sub-Saharan region, catering to an audience of distributors,
government representatives, laboratory executives, and
purchasing/procurement managers from the South African Development
Community region and around the world, who attend to meet with
world-class suppliers and manufacturers.
Co-Dx believes that the trade show will contribute valuable
insight into markets that are anticipated to play an important role
in the Company's future. In a report issued in September 2023, the WHO estimated that 2.5
million people contracted tuberculosis (TB) in the African Region
in 2021, while noting that a large gap also remains between
estimated TB cases and those identified. Co-Dx has several
infectious disease tests in varying stages of development on the
Company's upcoming Co-Dx™ PCR at-home and point-of-care platform*,
including a test for TB.
Additionally, in an update on its Logix Smart® Mpox (2-Gene) RUO
test last month, the Company reported that an in silico analysis
shows that the test should retain full reactivity against known
mpox strains. This followed the respective declarations in August
by the Africa CDC and WHO of mpox (formerly monkeypox) as a public
health emergency of continental security (PHECS) and a public
health emergency of international concern (PHEIC).
More information about the conference can be found here. Parties
interested in learning more about the Company's diagnostic products
are invited to visit Booth H1/B1.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx
PCR Pro™, mobile app, and all associated tests and software) is
subject to review by the FDA and/or other regulatory bodies and is
not available for sale. The Co-Dx PCR Pro instrument and Co-Dx
COVID-19 Test are currently under review by the FDA.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
Forward-Looking Statements:
This press
release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA) that are subject to a number of risks and uncertainties.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding our preparation for
introducing a new PCR diagnostic platform designed for at-home and
point-of-care use and that African markets may play an important
role in the Company's future. Actual results may differ
materially from those contemplated or anticipated by such
forward-looking statements. Readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. There can be no assurance that any of the anticipated
results will occur on a timely basis or at all due to certain risks
and uncertainties, a discussion of which can be found in our Risk
Factors disclosure in our Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (SEC) on March 14,
2024, and in our other filings with the SEC. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-medlab-africa-in-cape-town-on-oct-22-24-2024-302281585.html
SOURCE Co-Diagnostics
